文献速递眼底病与葡萄膜炎

COVID-19疫苗接种后非感染性葡萄膜炎风险:一项全国性回顾性队列研究

Noninfectious Uveitis Risk After COVID-19 Vaccination: A Nationwide Retrospective Cohort Study.
PubMed 文献 · Am J Ophthalmol · 2023-09-20

该全国性回顾性队列研究纳入5,185,153名接种首剂COVID-19疫苗者与2,680,164名未接种未感染对照,观察180天。多变量分析显示接种后60天内非前部葡萄膜炎风险升高(HR 1.27,95%CI 1.03-1.55),61-180天风险亦升高(HR 1.39,95%CI 1.20-1.62);女性亚组风险更高。结论认为COVID-19疫苗接种可能适度增加非前部葡萄膜炎风险,尤其女性。

要点

  • 接种后60天内非前部葡萄膜炎风险升高(HR 1.27,95%CI 1.03-1.55)。
  • 接种后61-180天非前部葡萄膜炎风险升高(HR 1.39,95%CI 1.20-1.62)。
  • 女性亚组早期和延迟非前部葡萄膜炎风险均升高(HR 1.44和HR 1.78)。

核心结论

  • COVID-19疫苗接种可能适度增加非前部葡萄膜炎风险,尤其女性。
  • 无论葡萄膜炎部位和发病时间,既往非感染性葡萄膜炎史均为最显著风险因素,风险比高达100至200。

研究设计与样本

  • 回顾性人群队列研究,暴露组纳入5,185,153名接种首剂COVID-19疫苗者,未暴露未感染对照组纳入2,680,164名个体,自索引日期起观察180天。

主要发现

  • 多变量分析显示接种后60天内非前部葡萄膜炎风险升高(HR 1.27,95%CI 1.03-1.55),61-180天风险升高(HR 1.39,95%CI 1.20-1.62)。
  • 女性亚组早期非前部葡萄膜炎风险升高(HR 1.44,95%CI 1.08-1.92),延迟非前部葡萄膜炎风险升高(HR 1.78,95%CI 1.43-2.20)。
  • 无论葡萄膜炎部位和发病时间,既往非感染性葡萄膜炎史为最显著风险因素,风险比范围为100至200。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 尽管进行了调整,暴露组仍可能存在偏倚,原因在于未暴露组与暴露组之间存在显著差异,且未暴露组非前部葡萄膜炎发生率低。
  • 未来研究应通过评估既往非感染性葡萄膜炎患者的葡萄膜炎风险、扩大样本量或进行队列匹配来完善这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence and risk of noninfectious uveitis (NIU) following COVID-19 vaccination compared with an unvaccinated, uninfected control group. DESIGN: Retrospective population-based cohort study. METHODS: We included 5,185,153 individuals who received the first vaccine dose in the exposed group and 2,680,164 individuals in the unexposed, uninfected control group. The study observed for 180 days from their index date. Cumulative incidence and risk of NIU following COVID-19 vaccination, and attributable risk factors were assessed. RESULTS: Multivariable analysis showed elevated risk of nonanterior NIU within 60 days (hazard ratio [HR] 1.27 [95% confidence interval {CI} 1.03-1.55] and 61-180 days (HR 1.39 [95% CI 1.20-1.62]). Subgroup analysis highlighted an increased risk in females for early and delayed nonanterior uveitis (HR 1.44 [95% CI 1.08-1.92]; HR 1.78 [95% CI 1.43-2.20], respectively). Regardless of the location and onset timing of uveitis, a history of NIU was identified as the most significant risk factor, with a high hazard ratio ranging from 100 to 200. CONCLUSIONS: COVID-19 vaccination may modestly increase the risk of nonanterior uveitis especially in females. Despite adjustments, bias may persist in the exposed group, owing to significant differences between unexposed and exposed groups and low incidence of nonanterior uveitis in the unexposed group. Future research should aim to refine these findings by assessing uveitis risk in prior NIU patients and by enlarging the sample size or cohort matching.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Chang MS, Kim HR, Kim S, et al. Noninfectious Uveitis Risk After COVID-19 Vaccination: A Nationwide Retrospective Cohort Study. Am J Ophthalmol. 2023. PMID: 37739204. doi:10.1016/j.ajo.2023.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。